NFKB1 and neoplasm: In radiotherapy, the activation of the NC NF‐κB pathway in DCs negatively regulated irradiation‐induced anti‐tumor immunity by controlling the type I IFN expression.[26] This underscores a limitation in the immune response during radiotherapy, particularly mediated through the NC NF‐κB pathway.